Esperion Therapeutics, Inc. (0IIM.L)
USD 1.3
(-1.19%)
USD 1.3
(-1.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 660.79 Million USD | 15.58% |
| 2022 | 571.71 Million USD | -1.18% |
| 2021 | 578.53 Million USD | 28.74% |
| 2020 | 449.39 Million USD | 131.05% |
| 2019 | 194.49 Million USD | 202.33% |
| 2018 | 64.33 Million USD | 94.1% |
| 2017 | 33.14 Million USD | 99.53% |
| 2016 | 16.61 Million USD | 99.82% |
| 2015 | 8.31 Million USD | -15.09% |
| 2014 | 9.79 Million USD | 132.96% |
| 2013 | 4.2 Million USD | -82.99% |
| 2012 | 24.7 Million USD | 199.91% |
| 2011 | 8.23 Million USD | 0.0% |
| 2002 | 12.66 Million USD | 6.94% |
| 2001 | 11.84 Million USD | 16.26% |
| 2000 | 10.18 Million USD | 96.48% |
| 1999 | 5.18 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 696.53 Million USD | 4.37% |
| 2024 Q1 | 667.35 Million USD | 0.99% |
| 2023 Q3 | 631.3 Million USD | 4.07% |
| 2023 FY | 660.79 Million USD | 15.58% |
| 2023 Q4 | 660.79 Million USD | 4.67% |
| 2023 Q2 | 606.6 Million USD | 4.32% |
| 2023 Q1 | 581.48 Million USD | 1.71% |
| 2022 Q3 | 606.92 Million USD | 1.89% |
| 2022 FY | 571.71 Million USD | -1.18% |
| 2022 Q4 | 571.71 Million USD | -5.8% |
| 2022 Q2 | 595.67 Million USD | 0.64% |
| 2022 Q1 | 591.89 Million USD | 2.31% |
| 2021 Q4 | 578.53 Million USD | -1.6% |
| 2021 FY | 578.53 Million USD | 28.74% |
| 2021 Q3 | 587.96 Million USD | 0.55% |
| 2021 Q2 | 584.77 Million USD | 6.71% |
| 2021 Q1 | 548 Million USD | 21.94% |
| 2020 Q1 | 229.88 Million USD | 18.2% |
| 2020 Q3 | 242 Million USD | -1.17% |
| 2020 FY | 449.39 Million USD | 131.05% |
| 2020 Q2 | 244.86 Million USD | 6.51% |
| 2020 Q4 | 449.39 Million USD | 85.69% |
| 2019 Q3 | 186.75 Million USD | 4.06% |
| 2019 Q4 | 194.49 Million USD | 4.14% |
| 2019 FY | 194.49 Million USD | 202.33% |
| 2019 Q1 | 61.47 Million USD | -4.45% |
| 2019 Q2 | 179.48 Million USD | 191.97% |
| 2018 Q3 | 42.28 Million USD | 20.94% |
| 2018 Q1 | 30.04 Million USD | -9.34% |
| 2018 FY | 64.33 Million USD | 94.1% |
| 2018 Q4 | 64.33 Million USD | 52.14% |
| 2018 Q2 | 34.96 Million USD | 16.36% |
| 2017 Q4 | 33.14 Million USD | -5.29% |
| 2017 Q2 | 31.13 Million USD | 40.31% |
| 2017 Q1 | 22.19 Million USD | 33.59% |
| 2017 FY | 33.14 Million USD | 99.53% |
| 2017 Q3 | 34.99 Million USD | 12.4% |
| 2016 Q1 | 8.27 Million USD | -0.45% |
| 2016 FY | 16.61 Million USD | 99.82% |
| 2016 Q4 | 16.61 Million USD | 72.83% |
| 2016 Q2 | 9.5 Million USD | 14.86% |
| 2016 Q3 | 9.61 Million USD | 1.1% |
| 2015 Q4 | 8.31 Million USD | -16.13% |
| 2015 FY | 8.31 Million USD | -15.09% |
| 2015 Q1 | 10.79 Million USD | 10.26% |
| 2015 Q2 | 10.5 Million USD | -2.71% |
| 2015 Q3 | 9.91 Million USD | -5.62% |
| 2014 Q1 | 3.18 Million USD | -24.14% |
| 2014 Q3 | 10.3 Million USD | -0.68% |
| 2014 Q4 | 9.79 Million USD | -5.02% |
| 2014 FY | 9.79 Million USD | 132.96% |
| 2014 Q2 | 10.37 Million USD | 225.53% |
| 2013 Q1 | 2.52 Million USD | -89.79% |
| 2013 Q2 | 6.64 Million USD | 163.54% |
| 2013 Q3 | 3.34 Million USD | -49.69% |
| 2013 Q4 | 4.2 Million USD | 25.71% |
| 2013 FY | 4.2 Million USD | -82.99% |
| 2012 Q4 | 24.7 Million USD | 0.0% |
| 2012 FY | 24.7 Million USD | 199.91% |
| 2011 FY | 8.23 Million USD | 0.0% |
| 2003 Q1 | 12.67 Million USD | 0.12% |
| 2003 Q3 | 14.37 Million USD | -0.75% |
| 2003 Q2 | 14.48 Million USD | 14.2% |
| 2002 FY | 12.66 Million USD | 6.94% |
| 2002 Q2 | 12.53 Million USD | -1.99% |
| 2002 Q3 | 12.02 Million USD | -4.06% |
| 2002 Q1 | 12.78 Million USD | 8.0% |
| 2002 Q4 | 12.66 Million USD | 5.31% |
| 2001 Q2 | 11.87 Million USD | 19.12% |
| 2001 Q4 | 11.84 Million USD | -2.98% |
| 2001 FY | 11.84 Million USD | 16.26% |
| 2001 Q1 | 9.97 Million USD | -2.1% |
| 2001 Q3 | 12.2 Million USD | 2.75% |
| 2000 Q1 | 5.4 Million USD | 0.0% |
| 2000 FY | 10.18 Million USD | 96.48% |
| 2000 Q2 | 7.34 Million USD | 35.93% |
| 2000 Q3 | 10.02 Million USD | 36.42% |
| 2000 Q4 | 10.18 Million USD | 1.66% |
| 1999 FY | 5.18 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -5.893% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -424.025% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -6.975% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -149.604% |
| bluebird bio, Inc. | 424.62 Million USD | -55.618% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -861.023% |
| Imunon, Inc. | 8.53 Million USD | -7646.271% |
| Editas Medicine, Inc. | 150.05 Million USD | -340.362% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 96.787% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 81.15% |
| Myriad Genetics, Inc. | 312.9 Million USD | -111.182% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 35.179% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -35.558% |
| Verastem, Inc. | 71.18 Million USD | -828.271% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.04% |
| Waters Corporation | 3.47 Billion USD | 80.993% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.726% |
| Biogen Inc. | 12.04 Billion USD | 94.514% |
| Nektar Therapeutics | 267.04 Million USD | -147.444% |
| Perrigo Company plc | 6.04 Billion USD | 89.062% |
| Dynavax Technologies Corporation | 375.02 Million USD | -76.199% |
| Illumina, Inc. | 4.36 Billion USD | 84.865% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1778.466% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -237.589% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -157.639% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1671.935% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 65.039% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -701.609% |
| Evolus, Inc. | 209.68 Million USD | -215.132% |
| Adicet Bio, Inc. | 37.12 Million USD | -1680.145% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1542.694% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 90.702% |
| FibroGen, Inc. | 585.72 Million USD | -12.815% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 86.564% |
| OPKO Health, Inc. | 622.47 Million USD | -6.155% |
| Homology Medicines, Inc. | 118.53 Million USD | -457.473% |
| Geron Corporation | 146.12 Million USD | -352.203% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 83.686% |
| Exelixis, Inc. | 678.44 Million USD | 2.602% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -3192.262% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -5171.98% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -163.464% |
| Zoetis Inc. | 9.29 Billion USD | 92.891% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -66.337% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1243.725% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 87.169% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1264.0% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 74.618% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 72.527% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -475.541% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 59.939% |
| Blueprint Medicines Corporation | 918.64 Million USD | 28.069% |
| Insmed Incorporated | 1.66 Billion USD | 60.236% |
| TG Therapeutics, Inc. | 169.08 Million USD | -290.803% |
| Incyte Corporation | 1.59 Billion USD | 58.5% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 44.265% |